Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Exclusion Criteria17

• With a history of allergic to platinum drugs and similar compounds
• Evidence of distant metastasis or radiation encephalopathy or leptomeningeal disease (LMD)
• Have received radioactive seed implantation in the treatment area
• Suffer from uncontrolled disease which could interfere with treatment
• Suffered from another malignant tumor or multiple primary tumors at the same time within 5 years (excluding fully treated basal cell or squamous cell skin cancer, cervical cancer in situ, etc.)
• The patient has surgical contraindications: such as severe cardiopulmonary disease, coagulation dysfunction and so on
• The patients have autoimmune diseases
• The patient is using immunosuppressive agents or systemic glucocorticoid to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other), and continues to use it within 2 weeks before the first administration
• Severe allergic reaction to other monoclonal antibodies
• Previously received PD-1 monoclonal antibody, CTLA-4 monoclonal antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway) treatment
• Live vaccines have been inoculated within 4 weeks before the first administration or during the study period
• The patient has any situation that may hinder study compliance or the safety during the study period
• Existence of serious neurological or psychiatric diseases, such as dementia and seizures
• Uncontrolled active infection
• Pregnant or breastfeeding women
• Those who have no personal freedom and independent capacity for civil conduct
• There are other situations that are not suitable for entry into the study